JSJenny Stritzelberger

Jenny Stritzelberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jenny Stritzelberger has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Hajo Hamer

    Epilepsy Center, Department of Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    15 shared publications
  • Caroline Reindl

    Epilepsy Center, Department of Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany(1)

    8 shared publications
  • Stephanie Gollwitzer

    Epilepsy Center, Department of Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    8 shared publications
  • Johannes Dominik Lang

    Epilepsy Center, Department of Neurology, University Hospital Erlangen Friedrich Alexander University Erlangen–Nuremberg Erlangen Germany

    7 shared publications
  • Stefan Schwab

    Epilepsy Center, Dept. of Neurology, Friedrich-Alexander University of Erlangen-Nürnberg, Full Member of EpiCare, Erlangen, Germany

    7 shared publications
  • Arnd Dörfler

    Department of Neuroradiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg , Erlangen

    5 shared publications

Latest Publications

  • Tumor-associated epilepsy at diagnosis in glioblastoma patients reveals an inflammatory molecular signature and is associated with better overall survival

    by Lilyana Dimova, Jenny Stritzelberger, Diyan Dimov, Jonas Ort, Hussam Aldin Hamou, Hans Clusmann, Oliver Schnell, Hajo Hamer, Florian Putz, Stefanie Corradini, et al.

    Background: Glioblastoma (GB) is the most aggressive primary brain tumor in adults. Tumor-associated epilepsy (TAE) at diagnosis is common, yet its prognostic significance remains unclear. Methods: We analyzed a retrospective multicenter test cohort of 855 GB patients (Aachen, Hamburg, Bielefeld) and validated findings in a prospectively collected cohort of 344 patients (Erlangen). Survival was assessed using multivariable Cox regression, propensity score matching, and interaction modeling of TAE and extent of resection (EOR). Molecular profiling included methylation-based classification, epigenetic deconvolution, and spatial transcriptomics. Results: Tumor-associated epilepsy was independently associated with improved survival (hazard ratio [HR] 0.81, 95% CI 0.69-0.99, P = .036, absolute survival advantage ∼4-5 months). This effect was validated in the independent cohort (C-index 0.68, 95% CI 0.62–0.74) and persisted in propensity-matched analyses (HR 0.74, 95% CI 0.56-0.96, P = .027). Interaction modeling revealed that gross total resection (GTR) improved survival in both groups but particularly in patients with TAE (EOR interaction HR 0.69, 95% CI 0.49-0.99, P = .041). In this subgroup, partial resection provided no significant advantage over biopsy, whereas patients without seizures benefited incrementally from both partial resection and GTR. Molecular analysis demonstrated enrichment of the RTK II subtype, differentiated cell states, and an inflammatory microenvironment in GB with TAE; tumors without seizures displayed neuronal and stem-like features. Functional validation using electrogenomics showed that GB cortical slices with increased inflammatory score exhibited synchronization of action potentials characteristic for seizure-like epileptiform activity. Conclusions: Tumor-associated epilepsy at diagnosis is a favorable prognostic marker in GB, defining a biologically distinct subgroup. Seizure status modifies the prognostic effect of surgical resection, underscoring the importance of GTR particularly in patients presenting with TAE.


  • Open Access

    Persons with epilepsy have an elevated radiosensitivity, which may be mitigated by folic acid

    by Melissa Kleber, Lukas C. F. Kuhlmann, Anabel Knabe, Jennifer Lainer, Stefan Schwab, Hajo M. Hamer, Stefanie Corradini, Luitpold Distel, Jenny Stritzelberger

    Introduction: Patients undergoing radiotherapy for cancer usually have several other comorbidities and are taking various medications. Both of these factors can affect the individual radiation sensitivity of normal tissue. We therefore studied persons with epilepsy (PWE) to determine whether they had altered radiation sensitivity. Material and Methods: Blood samples were collected from 105 adult patients with epilepsy and compared to those of healthy individuals and oncological patients. The samples were irradiated ex vivo and analyzed by 3-color fluorescence in situ hybridization. In each patient, aberrations were analyzed in 200 metaphases of chromosomes 1, 2, and 4 and scored as breaks. Radiosensitivity was determined by mean breaks per metaphase (B/M) and compared to both healthy donors and oncologic patients. Results: Radiosensitivity (B/M) of the PWE ( n = 105, B/M: 0.478) was clearly increased compared to healthy individuals ( n = 209, B/M: 0.420) and oncological patients (rectal patients and breast cancer patients, n = 319, B/M = 0.442). Antiseizure medications tended to increase radiation sensitivity. The use of perampanel (0.505 B/M; p = 0.081) and lacosamide (0.521 B/M; p = 0.014) led to a clear increase in radiation sensitivity. Male PWE (0.502B/M, p = 0.004) were distinctly radiosensitive which may be potentially explained by the fact that women were recommended to take high doses of folic acid according to German guidelines at the time of the study. Factors like seizure frequency, epilepsy duration, polytherapy and comedication did not contribute to increased radiosensitivity. Conclusion: PWE were clearly increased radiosensitive compared to healthy individuals and oncological patients. Male PWEs were found to be more sensitive than female PWEs. This may be due to their higher intake of folic acid, a substance which can protect against radiation.

  • Open Access

    Spectral profile of early ictal EEG patterns in status epilepticus predicts therapy response

    by Tamara M. Welte, Susanne Noell, Rüdiger Hopfengärtner, Stefan Rampp, Jenny Stritzelberger, Johannes D. Lang, Caroline Reindl, Kosmas Macha, Julia Koehn, Joji B. Kuramatsu, et al.


  • Open Access

    Seizures in children and adolescents with high-grade glioma: a retrospective, monocentric analysis

    by Jenny Stritzelberger, Anna Gesmann, Daniel Delev, Stefan Schwab, Florian Putz, Markus Metzler, Regina Trollmann, Hajo Hamer


  • Open Access

    Validity of Empatica E4 Wristband for Detection of Autonomic Dysfunction Compared to Established Laboratory Testing

    by Jenny Stritzelberger, Marie Kirmse, Matthias C. Borutta, Stephanie Gollwitzer, Caroline Reindl, Tamara M. Welte, Hajo M. Hamer, Julia Koehn

    Background: Heart rate variability (HRV) is a well-established marker of autonomic nervous system (ANS) activity. It is also an important tool for investigating cardiovascular and neurological health. Changes in HRV have been associated with epilepsy and sudden unexpected death in epilepsy (SUDEP), conditions in which autonomic dysregulation is believed to play a significant role. HRV is traditionally measured using electrocardiography (ECG) under standardized laboratory conditions. Recently, however, wearable devices such as the Empatica E4 wristband have emerged as promising tools for continuous, noninvasive HRV monitoring in real-life, ambulatory, and clinical settings where laboratory infrastructure may be lacking. Methods: We evaluated the validity and clinical utility of the Empatica E4 wristband in two cohorts. In the first cohort of healthy controls (n = 29), we compared HRV measures obtained with the E4 against those obtained with a gold-standard laboratory ECG device under seated rest and metronomic breathing conditions. In persons with epilepsy (PWE, n = 42), we assessed HRV across wake and sleep states, as well as during exposure to sodium channel blockers. This was done to determine whether the device could detect physiologically and clinically meaningful changes in autonomic nervous system (ANS) function. Results: In healthy participants, the Empatica E4 provided heart rate (HR), root mean square of successive R-R intervals (RMSSD), and standard deviation of all interbeat intervals (SDNN) values that were strongly correlated with laboratory measurements. Both devices detected the expected increase in RMSSD during metronomic breathing; however, the E4 consistently reported higher absolute values than the ECG. In patients with epilepsy (PWE), the E4 reliably captured parasympathetic activation during sleep and detected a significant reduction in heart rate variability (HRV) in patients taking sodium channel blockers, demonstrating its sensitivity to clinically relevant autonomic changes. Conclusions: The Empatica E4 wristband is valid for measuring HRV in research and clinical contexts. It can detect modulations of ANS activity that are physiologically meaningful. While HRV metrics were robust, other signals, such as electrodermal activity and temperature, were less reliable. These results highlight the potential of wearable devices as practical alternatives to laboratory-based autonomic testing, especially in emergency and resource-limited settings, and emphasize their importance in epilepsy care risk assessment.


  • Open Access

    Factors influencing neurologists' prescribing of antiseizure medication: The role of physician biography and patient characteristics

    by Jenny Stritzelberger, Katrin Walther, David Olmes, Stephanie Gollwitzer, Tamara M. Welte, Johannes D. Lang, Caroline Reindl, Stefan Schwab, Peter Kriwy, Hajo M. Hamer

  • Open Access

    Object naming after epilepsy surgery in the dominant left temporal lobe: risk factors, time course and long-term outcome

    by Katrin Walther, Caroline Reindl, Michael Schwarz, Stephanie Gollwitzer, Burkhard S Kasper, Johannes Dominik Lang, Jenny Stritzelberger, Sebastian Brandner, Karl Rössler, Yining Zhao, et al.

    Background Deterioration in naming function is a common sequelae after epilepsy surgery in the language-dominant temporal lobe but information on recovery and long-term outcome is scarce. We, therefore, assessed short-term and long-term outcome of object naming in patients undergoing surgery in the temporal lobe and determined factors affecting deterioration and recovery of naming function. Method Object naming (Boston naming test) before surgery, at early follow-up (FU, 6–12 months) and late FU (≥2 years) was assessed in people with epilepsy (PWE) undergoing resections in the language-dominant left and non-dominant right temporal lobe. Results Sixty-six patients with left temporal lobe epilepsy (LTLE) and 87 control patients with right temporal lobe epilepsy (RLTE) were included. At early FU, 28 patients with LTLE (42%) and three patients with RTLE (3%) showed a significant naming decline. In patients with LTLE, risk for deterioration increased with lower verbal memory before surgery, older age at seizure onset and was particularly high with posterior temporal resections (≥40 mm from the temporal pole) and seizure onset >16 years. Of the patients with LTLE with early naming decline, 11 patients (39%) recovered fully in their naming abilities at late FU, averaging almost 10 years. Recovery was associated with the degree of postoperative naming decline at early FU. PWE with a decline of less than 10 items (Conclusions In our cohort, less than 50% of PWE showed significantly deteriorated naming function after resection of the dominant temporal lobe. If a decline occurred, it appeared to recover to a certain degree and remained as a permanent deficit in 26% of the patients. Long-term outcome of visual object naming can be predicted by the degree of early postoperative decline.


  • Open Access

    Spectral properties of bursts in therapeutic burst suppression predict successful treatment of refractory status epilepticus

    by Stephanie Gollwitzer, Rüdiger Hopfengärtner, Stefan Rampp, Tamara Welte, Dominik Madžar, Johannes Lang, Caroline Reindl, Jenny Stritzelberger, Julia Koehn, Joji Kuramatsu, et al.


  • Open Access

    Radiosensitivity in individuals with tuberous sclerosis complex

    by Lukas Kuhlmann, Jenny Stritzelberger, Rainer Fietkau, Luitpold V. Distel, Hajo M. Hamer

    Benign tumors, but rarely cancer, are common in patients with tuberous sclerosis complex (TSC). Blood samples from patients undergoing treatment for TSC at our institution were analyzed for their individual sensitivity to ionizing radiation. Blood samples were collected from 13 adult patients with TSC. The samples were irradiated ex vivo and analyzed by 3-color fluorescence in situ hybridization. In each patient, aberrations were analyzed in 200 metaphases of chromosomes 1, 2, and 4 and scored as breaks. Radiosensitivity was determined by mean breaks per metaphase (B/M) and compared to both healthy donors and oncologic patients. The radiosensitivity (B/M) of the TSC patient cohort (n = 13; female: 46.2%, B/M: 0.48 ± 0.11) was clearly increased compared to healthy individuals of similar age (n = 90; female: 54.4%; B/M: 0.40 ± 0.09; p = 0.001). There was no difference compared to age-matched oncological patients (n = 78; female: 67.9%; B/M 0.49 ± 0.14; p = 0.246). Similarly, the proportion of radiosensitive (B/M > 0.5) and distinctly radiosensitive individuals (B/M > 0.6) was increased in the TSC and oncological patient cohorts (TSC: 30.8% and 7.7%, oncological patients: 46.2% and 14.1%) compared to the healthy individuals (11.1% and 2.2%). Although patients with TSC develop mostly benign and rarely malignant tumors, they are similarly sensitive to radiation as patients with malignant tumors.


  • Open Access

    The course of tumor-related epilepsy in glioblastoma patients: A retrospective analysis

    by Jenny Stritzelberger, Anna Gesmann, Imke Fuhrmann, Martin Uhl, Sebastian Brandner, Tamara-M. Welte, Leah Schembs, Arnd Dörfler, Roland Coras, Werner Adler, et al.